# US 11,304,926 B2 · Application of transient receptor potential cation channel TRPV3 in developing drug for preventing or treating psoriasis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,926 B2
- Document ID: US11304926B2
- Status: Granted
- Kind: B2
- Application number: 16/849,555
- Filed: 2020-04-15
- Published: 2020-08-06
- Granted: 2022-04-19
- Earliest claimed: 2019-01-08
- Assignees: China Pharmaceutical University
- Applicants: China Pharmaceutical University
- Inventors: Zhengyu Cao; Yujing Wang; Zhiqi Yin
- Web page: https://patentgrep.com/patent/US11304926B2

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 17/06: Antipsoriatics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pathophysiological effect of a transient receptor potential cation channel, subfamily V, member 3 (TRPV3) on psoriasis, which can be used to develop a drug for preventing or treating psoriasis. The invention further discloses an application of Scutellarein as a TRPV3 inhibitor in preparing a drug for preventing or treating psoriasis. When a drug containing the TRPV3 inhibitor discovered according to the invention or provided by the invention is used for preventing or treating psoriasis, good prevention or treatment effects can be achieved.

## Claims

### Claim 1

A method for screening a drug for treating a transient receptor potential cation channel (TRPV3)-related psoriasis comprising the following steps: culturing a cell line expressing the TRPV3, adding Fluo-4, adding a test drug and 2-aminoethoxybiphenylborate (2-APB), recording a fluorescence signal at a wavelength between 515 nm and 575 nm as a basic fluorescence signal when excited at a wavelength of 488 nm, adding the 2-APB, recording the fluorescence signal as a response fluorescence signal, the test drug is a candidate drug for treating the transient receptor potential cation channel (TRPV3)-related psoriasis when a value of the response fluorescence signal is bigger than that of the basic fluorescence signal.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the cell line expressing TRPV3 is prepared by transfecting mTRPV3 plasmid into HEK-293 cell; wherein the mTRPV3 plasmid comprises a murine TRPV3 cDNA that is controlled by an eukaryotic promotor.